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A new platform constituted by engineered responsive nanoparticles transported by human mesenchymal stem cells is 
here presented as a proof of concept. Ultrasound-responsive mesoporous silica nanoparticles are coated with 
polyethylenimine to favor their effective uptake by decidua-derived mesenchymal stem cells. The responsive-release 
ability of the designed nanoparticles is confirmed, both in vial and in vivo. In addition, this capability is maintained inside 
the cells used as carriers. The migration capacity of the nanoparticle-cell platform towards mammary tumors is assessed in 
vitro. The efficacy of this platform for anticancer therapy is shown against mammary tumor cells by inducing the release of 
doxorubicin only when the cell vehicles are exposed to ultrasound. 
Introduction 
In the last few years research in nanomedicine is focusing on 
developing nanocarriers for targeted drug delivery combined 
with on-demand release behavior.
1,2
 In this sense, porous 
nanoparticles with great loading capacity and tunable surface 
properties have become a promising alternative for certain 
biomedical applications such as cancer therapy. Among those 
materials, mesoporous silica nanoparticles present high drug 
adsorption capacity because of their available pores, and they 
are very robust, which allows further chemical modification of 
their surface.
3–5
 The release of the transported drugs can be 
controlled through a stimuli-responsive release that can be 
achieved through different trigger mechanisms, which can be 
endogenous, such as changes in pH,
6
 redox potential,
7
 and 
presence of specific enzymes or analytes;
8
 or exogenous, such 
as temperature,
9
 light,
10,11
 magnetic fields,
12,13
 electronic fields 
or ultrasounds.
14,15
  
An ideal nanocarrier for drug delivery in cancer therapy 
should be capable of specifically targeting tumor tissue 
avoiding premature release of the payload, and releasing high 
concentrations of the cargo only at the diseased tissues.
16–18
 
Targeted nanoparticles towards tumors can be accomplished 
by either passive or active targeting, or by a combination of 
both.
19
 Passive targeting is based on the combination of two 
features of tumor tissues: high permeability and enhanced 
retention, in what is called Enhanced Permeation and 
Retention (EPR) effect.
20,21
 Nanoparticles tend to accumulate 
in tumor zones due to the abnormal architecture and 
permeability of the tumor blood vessels. Additionally, there is 
a poor drainage which results in the retention of the 
nanoparticles within the tissue.
20
 On the other hand, active 
targeting is based on grafting affinity ligands on the surface of 
nanoparticles able to interact with specific membrane 
receptors overexpressed by tumor cells, leading to specific 
retention and uptake by the targeted cancer cells.
2,19
  
However, despite the recent advances in nanoparticles 
research for biomedicine, the translation of targeted 
nanocarriers (both passive and active targeting) to the clinic 
remains to be a challenge.
22–24
 In a totally different approach, 
cell-based therapies have been investigated as transporters of 
nanoparticles for cancer treatment.
25,26
 In this sense, Human 
Mesenchymal Stem Cells are multipotent cells that maintain 
and regenerate connective tissues, with inherent migratory 
properties, in response to inflammation and/or injury.
27–29
 
This migratory and homing capacities have suggested their use 
as drug delivery agents for the treatment of isolated and 
metastatic tumors.
26,30–32
 Conventionally, bone marrow and 
adipose tissue are the common sources of adult MSCs, 
although the isolation techniques are invasive and not very 
efficient in terms of isolated cell quantities.
33
 Besides, the 
donor age strongly influences the number, proliferation and 
differentiation capabilities, which decline with donor age.
34
 In 
the last few years our research group has been investigating 
an additional source of MSCs from the human decidua of the 
placenta, which are isolated avoiding invasive procedures.
33
 
Decidua Mesenchymal Stem Cells (DMSCs) present a number 
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of advantages over conventional MSCs, such as: they are very 
easy to obtain without invasive techniques; they constitute a 
homogeneous population with high proliferation and 
differentiation capacities; they are adult stem cells from the 
maternal part of the placenta, with low or non-immune 
response and genetically stable during expansion.
33
 
Additionally, DMSCs present migratory properties towards 
tumors, both in vitro and in vivo, and, additionally, they inhibit 
the growth of primary tumors and the development of new 
tumors.
34
 Consequently, DMSCs seem to be excellent carriers 
of pharmaceutical agents towards tumor tissues. However, if 
the cells are carrying cytotoxic agents, some strategy should 
be developed to ensure DMSCs survival during transport. An 
interesting approach would consist of loading the cytotoxic 
cargo on stimuli-responsive nanoparticles for drug delivery. 
Those smart nanocarriers would be introduced into the 
DMSCs, which would transport them to the targeted tissue. 
The application of an external stimulus would trigger the 
release of the cytotoxic drug. As a consequence, the drug 
would have to be released from the DMSCs to the surrounding 
tissue.
26,35
 The process by which hydrophobic cytotoxic 
molecules (like doxorubicin)
36,37
 can diffuse out of a 
transporting cell to kill surrounding cancer cells has been 
called the “bystander effect”.
38–40
 
In this manuscript we have developed a proof of concept 
cell-platform constituted by engineered ultrasound-responsive 
nanoparticles which are vectorized to tumor tissues by using 
DMSCs. The nanocarrier provides a controlled release, 
triggering the payload release on demand when a penetrating 
stimulus such us Ultrasounds would be applied. To the best of 
our knowledge this is the first time that human mesenchymal 
stem cells are employed as transporters that can release a 
therapeutic molecule on-demand. 
Results and discussion 
Engineered Ultrasound-Responsive Nanoparticles 
Ultrasound-Responsive Nanoparticles (UR-NPs) are composed 
of an ultrasound (US) responsive copolymer (poly(2-(2-
methoxyethoxy)ethylmethacrylate-co-2-tetrahydropyranyl 
methacrylate, p(MEO2MA-co-THPMA)), covalently grafted to 
the surface of MCM-41 type Mesoporous Silica Nanoparticles. 
The synthesis, characterization and behavior of these hybrid 
nanoparticles has been previously reported.
15
 The material 
presents negatively charged surface at the pore walls, due to 
the silanol groups, which permits to load a high amount of the 
cytotoxic drug doxorubicin within the pores.
41,35
 Then, the 
pores are closed with a responsive polymeric gate to avoid 
premature release. The application of an exogenous stimulus, 
such as ultrasound, enables the delivery of the maximum 
amount of drug possible.  
We have developed a cell-platform to transport the UR-
NPs selectively to tumor tissues. Once in the tumor, the 
cytotoxic agent would be released, damaging the cancer cells 
without affecting healthy tissues. In this combined approach, 
the NPs will provide the responsive drug release, while the 
biological component (DMSCs) will act as a specific vehicle to 
carry the NPs to the tumor. To obtain this goal, the 
nanoparticles must be internalized into the cell vehicles. 
Cellular uptake is generally enhanced employing 
internalization ligands or positively charged moieties on the 
surface of NPs.
42
 In this sense, polyethylenimine (PEI) is a 
synthetic cationic polymer that has been widely used to 
deliver oligonucleotides, siRNA and plasmid DNA to cells.
43,44
 
An interesting approach for effectively NPs internalization into 
cells consists on decorating the NPs surface with PEI. Cellular 
uptake of PEI-coated nanoparticles relies on the electrostatic 
interaction between the positively charged polymer and 
negatively charged cell membrane, in a charge-dependent 
mechanism that is not selective on the cell type.
43
 The above 
synthesized UR-NPs were coated with 1800 Da PEI (UR-
NPs@PEI), which is known to present low cytotoxicity, to 
conferee a positive charge on their external surface that will 
increase the amount of NPs internalized in DMSCs.
35
  
The presence of PEI in the particles was confirmed by 
different techniques: the Zeta Potential changed from 
negative to positive values after PEI coating (Figure 1). 
Thermogravimetric Analysis (TGA) data showed an organic 
matter percentage for the UR-NPs of 25 %, and 40 % for UR-
NPs@PEI, what indicated an estimate of 15 % of PEI in the 
final material. BET surface area decreased from 180 m
2
 g
-1
for 
UR-NPs to 70 m
2
 g
-1
 for UR-NPs@PEI.  Small angle X-ray 
diffraction patterns show that hexagonal pore order of the 
mesoporous silica nanoparticles was maintained (see Figure 
S1). The diameter and morphology of the NPs remains 
unmodified after the PEI coating, as it can be seen in the 
Scanning Electron Microscopy images (Figure 1). The 
mesoporous order can be appreciated in the Transmission 
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Electron Microscopy micrographs which also showed the 
presence of the US-responsive copolymer, or the copolymer 
plus the PEI, on the external surface of the mesoporous 
ordered NPs when the materials were stained with 
Phosphotungstic acid (Figure 1). As it will be seen throughout 
this article, nanoparticles labeled with different dyes have 
been employed, and their characterization did not show any 
significant differences when compared to the non-labeled 
nanoparticles. Several cargo molecules have also been loaded 
within the mesopores, in order to evaluate various aspects of 
the materials US-responsiveness. 
The US-responsiveness of UR-NPs@PEI was evaluated 
initially in vial, with a fluorescein release experiment. Taking 
into account that the gatekeeper copolymer shows a dual 
temperature-US responsiveness,
15
 fluorescein loading in UR-
NPs was performed at 4 
o
C. Under these conditions the 
polymer that acts as gatekeeper presented an open or 
hydrophilic conformation. After the dye loading process, the 
temperature was increased to 50 
o
C, inducing the copolymer 
to collapse, i.e. change to a hydrophobic conformation, closing 
the pore entrances. Then, loaded UR-NPs were coated with 
PEI. Dye release experiments (Figure 2) show that the 
behavior of the UR-NPs@PEI was similar to that of UR-NPs 
without coating; the presence of PEI coating did not induce 
any significant differences in the maximum percentage of 
fluorescein released with or without ultrasound (which was 
already reached after 16 h).
15
 As commented above, before US 
application, the polymeric gate is collapsed at the nanoparticle 
surface, blocking the pores and preventing cargo release. After 
insonation, one of the monomers in the polymeric gate 
(THPMA) is cleaved, yielding hydrophilic methacrylic acid. This 
change in the copolymer structure induces an increase in its 
hydrophilicity, triggering a change of conformation towards 
coil-like, which allows drug release from the material. The 
evaluation of this change in the polymeric gate has been 
demonstrated in our previous work.
15
 Here, we show that 
these engineered nanoparticles continue to behave as 
stimulus-responsive drug nanocarriers even though they have 
been coated with PEI. 
In vivo ultrasound-responsiveness of this material was 
checked loading Calcein-AM into UR-NPs@PEI. Calcein-AM is a 
low-fluorescent indicator that can be converted in vivo to 
highly-fluorescent Calcein due to the activity of esterases in 
the surrounding cells (Figure 3A). The Calcein-AM loaded 
material was injected subcutaneously and bilaterally in mice, 
monitoring the in vivo fluorescence before and after US 
application on one of the injection sites (Figure 3B-C). In order 
to point the location of the nanoparticles, Rhodamine B-
labeled UR-NPs@PEI were used for these experiments. Figure 
3B, corresponding to the fluorescence before US application, 
shows red fluorescence, delimiting the location of NPs due to 
the Rhodamine B labeling. No fluorescence was observed in 
the green channel (therefore, there had been no cargo 
release). After US application (1 MHz, 3 W cm
-2
, 10 min), red 
fluorescence indicated that the NPs were still present at the 
injection site and green fluorescence appeared only in the US- 
exposed area (Figure 3C). Taking into account that Calcein-AM 
inside the material pores is not accessible to the esterases 
from the cells, the presence of green fluorescence indicates 
that Calcein-AM was released from the material when the 
gatekeeper was opened due to ultrasound exposure. On the 
other hand, at the injection site without US application, there 
was no green fluorescence, which indicates that Calcein-AM is 
retained inside the nanoparticle pores and not exposed to 
esterases. The progressive increase of green fluorescence in 
vivo at different time points after ultrasound application can 
be seen in Figure S2. These results demonstrate the capability 
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of the UR-NPs@PEI to retain a cargo and release it when 
exposed to ultrasound in vivo.  
 
Ultrasound-Responsive Nanoparticles-Cell Platform 
After evaluating the in vial and in vivo responsiveness of UR-
NPs@PEI, we tested the interaction of the UR-NPs@PEI with 
the DMSCs which will act as transporters to the tumor tissue. 
To do so, the effect of UR-NPs@PEI at different concentrations 
on DMSCs viability was tested using the MTS and LDH assays 
(Figure S3). The results show no toxicity up to 200 μg mL
-1
, and 
a small toxicity at higher concentrations. Therefore, a 
concentration of 200 μg mL
-1 
was chosen for further 
experiments.  
Then, DMSCs were exposed to UR-NPs@PEI to study their 
internalization and retention in the cells. For these studies, the 
NPs were covalenty labeled with Fluorescein isothiocyanate 
(FITC). Figure 4A-C shows the fluorescence microscopy images 
of DMSCs stained with DAPI (nuclei) and Alexa Fluor
®
568 
phalloidin (cytoplasm) after incubation with labeled 
Nanoparticles (200 μg mL
-1 
for 2
 
h). As expected, microscopy 
images indicate that UR-NPs@PEI were internalized by the 
cells better than UR-NPs (Figure 4A-B). Moreover, the UR-
NPs@PEI escaped the endo-lysosomal compartment shortly 
after endocytosis, since NP fluorescence (green) and 
lysosomes (red) do not colocalize (Figure 4C). This behavior 
can be attributed to the Proton Sponge Effect provided by 
PEI.
43
 Under the acidic conditions of the lysosome, PEI (and 
other polycationic molecules) presents a very high positive 
charge. This induces the entrance in the lysosomes of chloride 
anions, accompanied by water. The lysosomes swell until they 
eventually burst, releasing their contents into the cytoplasm. 
The quantification of UR-NPs@PEI uptake (200 μg mL
-1 
for 2
 
h) 
by DMSCs by Flow Cytometry indicates a more successful 
internalization of UR-NPs@PEI compared to the nanoparticles 
without PEI (Figure 4D, Figure S4). The coated particles were 
also retained inside the cells for at least 6 days (Figure 4E), 
enough for the cells to reach the tumor, according to our 
previous work.
35
  
In addition, the UR-NPs@PEI retain their cargo after 
uptake by the DMSCs and are also able to release intracellular 
fluorescein after US application (Figure 5). For this 
experiment, Rhodamine B-labeled nanoparticles were used to 
simultaneously study the location of UR-NPs@PEI (red 
fluorescence) and their cargo (green fluorescence). Before US 
exposure, red and green fluorescence colocalize, indicating 
that the dye is retained inside UR-NPs@PEI. After insonation 
(1MHz, 3W cm
-2
, 5 min), a significant part of the dye diffuses 
out of the NPs and stains the cell cytoplasm (images taken 30 
min after insonation), as a consequence of the polymeric gates 
changing from a closed to an open conformation (Figure 2).  
The above results show the possibility to fabricate a cell 
platform containing US-responsive NPs inside the DMSCs for 
at least 6 days. To evaluate the effect of the cell-platform as 
transporters of cytotoxic molecules, the UR-NPs@PEI were 
loaded with doxorubicin (loaded amount was 2.94 ± 0.17 %). 
First, we incubated different concentrations of cytotoxic-
loaded NPs with the DMSCs for 2 h. After that, we washed the 
cells to eliminate the non-internalized NPs and cell viability 
was evaluated after 24 and 72 h (Figure 6). No toxicity was 
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observed up to a concentration of 200 µg mL
-1
. Therefore, 
these conditions (200 μg mL
-1 
UR-NPs@PEI for 2
 
h) were used 
for any further experiments. It is worth noting that, in our 
previous work, we had observed significant toxicity in DMSCs 
48 h after internalization caused by similar doxorubicin-loaded 
NPs but without stimulus-responsive gatekeeper.
35
 Thus, the 
NPs engineered in the present work are capable of retaining 
the cytotoxic drug inside them, preventing a premature 
leakage of the doxorubicin that could damage the transporting 
cells before they reach their target tissue.  
The next stage was to check the capability of the cell-NPs 
platform to reach the tumor site. In this sense, we performed 
a standardized in vitro cell migration assay towards the tumor 
homogenate to check if the presence of UR-NPs@PEI inside 
the cells has any negative impact in the DMSCs migration 
capacity. The results showed a high migration capacity of 
DMSCs towards tumor homogenate, which was maintained in 
our Platform carrying UR-NPs@PEI, even if those NPs were 
loaded with doxorubicin (DOX-Platform) (Figure 7). The 
amount of doxorubicin transported by the DOX-Platform was 
determined to be 0.47 ± 0.08 µg of doxorubicin per 10000 
DMSCs. The quantification of migrated cells shows no 
significant difference in cell migration due to UR-NP@PEI (with 
or without doxorubicin). These data indicate that stimulus 
responsive NPs containing a cytotoxic drug can be vectorized 
to the tumor site by DMSCs. 
Finally, in order to test whether this developed platform 
(UR-NPs@PEI inside DMSCs) could be useful for anticancer 
therapy, an in vitro co-culture experiment was carried out. The 
transporting cells (DMSCs and DOX-Platform) were divided in 
two groups and half of the samples were exposed to US (1 
MHz, 3 W cm
-2
, 5 min). Then, the DMSCs and DOX-Platforms 
with/without US exposure were seeded in a Transwell
®
 culture 
insert on top of a well that contained NMU cancer cells 
(DMSCs:NMU ratio was 1:2). After 24 and 48 h, the Transwell
®
 
inserts were removed and the NMU viability was evaluated by 
Alamar Blue test. Figure 8 shows that NMU cell viability is only 
affected when US is applied on DMSCs carrying doxorubicin-
loaded UR-NPs@PEI, but it remains unaffected in any of the 
other experimental conditions. Therefore, doxorubicin 
remains retained in UR-NPs@PEI inside DMSCs until the 
platform is exposed to US. After insonation, the nanoparticles 
release their cargo, which can diffuse towards tumor cells, 
inducing their death. Furthermore, that effect appears to be 
dose-dependent, since the reduction in NMU cell viability is 
smaller when the ratio DMSC:NMU is 1:5 (Figure S5). 
These results show the possibility to introduce cytotoxic-
loaded stimulus-responsive NPs in DMSCs as cell carriers. The 
migratory capacity of these cells to the tumor tissue was 
maintained in presence of UR-NPs. This platform was 
activated, i.e released the cytotoxic drug, just when an 
external stimulus was applied, in principle, when the cell 
platform reached the tumor tissue.  
Conclusions 
A cell platform to transport ultrasound-responsive 
nanoparticles towards tumor tissue has been developed. 
Experiments, both in vial and in vivo, have demonstrated the 
ultrasound responsiveness of the system, showing the 
capability to induce cargo release on-demand. These 
polyethylenimine-coated nanoparticles were efficiently 
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internalized by decidua-derived mesenchymal stem cells and 
they were retained for at least 6 days. The nanoparticle-cell 
construct also presented ultrasound-responsive cargo release 
capability. 
The tumor-tropic behavior of the cells was preserved when 
transporting doxorubicin-loaded nanoparticles. This 
doxorubicin carrying platform was able to induce the death of 
mammary cancer cells in vitro when it was exposed to 
ultrasound. 
The obtained results indicate that this platform could be 
employed to transport cytotoxic drugs specifically to tumors, 
and release them when exposed to ultrasound. 
Experimental section 
Reagents and Characterization Techniques. 
Following compounds were purchased from Sigma-Aldrich 
Inc.: Ammonium nitrate, cetyltrimethylammonium bromide 
(CTAB), tetraethyl orthosilicate (TEOS), methacrylic acid 
(MAA), pyridine, p-toluenesulfonic acid, toluene, 
dichloromethane (DCM), dihydropyran, dimethylformamide 
(DMF), 2-(2-methoxyethoxy) ethylmethacrylate (MEO2MA), 
4,4’-Azobis(4-cyanovaleric acid) (ABCVA), diethylether, N,N’-
dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), 
phosphate-buffered solution (PBS), fluorescein sodium salt, 
polyethylenimine (PEI) of 1800 Da, rhodamine-B 
isothyocianate and fluorescein isothyocianate (FTIC). Calcein-
AM was purchased from ThermoFisher Scientific. DMEM, 
penicillin-streptomicyn, non-essential aminoacids, trypsin-
EDTA were purchased from Invitrogen (Fisher Scientific, 
Madrid, Spain). Fetal bovine Serum is from Biowest (labClinics, 
Spain). Trans-well were purchased from Nunc (Fisher 
Scientific, Spain). These compounds were used without further 
purification. Tetrahydropyranyl methacrylate (THPMA) was 
synthesized as described previously.
15,45
  
The materials were analyzed by X-ray diffraction (XRD) in a 
Philips X-Pert MPD diffractometer equipped with Cu Kα 
radiation. Thermogravimetry and Differential Thermal Analysis 
(TGA/DTA) were performed in a Perkin Elmer Pyris Diamond 
TG/DTA analyzer, with 5 
o
C min
-1
 heating ramps, from room 
temperature to 600 
o
C. Fourier Transformed Infrared (FTIR) 
spectra were obtained in a Nicolet (Thermo Fisher Scientific) 
Nexus spectrometer equipped with a Smart Golden Gate ATR 
accessory. Surface morphology was analyzed by Scanning 
Electron Microscopy (SEM) in a JEOL 6400 Electron 
microscope. Transmission Electron Microscopy (TEM) was 
carried out with a JEOL JEM 2100 instrument operated at 200 
kV, equipped with a CCD camera (KeenView Camera). 
Phosphotungstic acid staining was employed to detect the 
presence of organic matter in the hybrid materials. N2 
adsorption was carried out on a Micromeritics ASAP 2010 
instrument; surface area was obtained by applying the 
Brunauer–Emmett–Teller (BET) method to the isotherm and 
the pore size distribution was determined by the Barrett-
Joyner-Halenda (BJH) method from the desorption branch of 
the isotherm. The mesopore size was determined from the 
maximum of the pore size distribution curve. The Z-potential 
was measured in deionized water by means of a Zetasizer 
Nano ZS (Malvern Instruments) equipped with a 633 nm “red” 
laser.  
 
Engineered US-Responsive Nanoparticles. 
Preparation of UR-NPs. A detailed description of the 
Ultrasonic-Responsive Nanoparticles (UR-NPs) synthesis 
method can be found in our previous work.
15
 Mesoporous 
silica nanoparticles were fabricated by the modified Stöber 
method from TEOS in the presence of CTAB as structure-
directing agent under basic and very dilute conditions.  
The random copolymer, poly(2-
(2methoxyethoxy)ethylmethacrylate-co-2-tetrahydropyranyl 
methacrylate, p(MEO2MA-co-THPMA), was synthesized by 
free radical polymerization from 2-(2-methoxyethoxy) 
ethylmethacrylate, MEO2MA, and 2-tetrahydropyranyl 
methacrylate, THPMA, in a MEO2MA:THPMA ratio of ca. 
90:10. The synthesis was performed at 80 
o
C overnight in DMF 
solution under inert atmosphere.  
Grafting the polymer nanogate to mesoporous silica 
nanoparticles to obtain UR-NPs was performed in two steps. 
First, the previously copolymer, p(MEO2MA-co-THPMA), was 
modified with an alkoxysilane (3-aminopropyl triethoxysilane) 
through DCC-NHS chemistry. Then, the sililated polymer was 
grafted to the silica nanoparticles surface through sol-gel 
chemistry. A ratio polymer:nanoparticles of 6:1 was used, and 
the sililated polymer was added in 3 steps to the 
nanoparticles.
15
 
FITC and Rhodamine B-labeled UR-NPs were prepared 
following the same procedure but using NPs covalently 
labeled with the fluorophore during NP synthesis as described 
elsewhere.
15,35
 
Preparation of UR-NPs@PEI. The synthesis of stimuli 
responsive nanoparticles coated with PEI (UR-NPs@PEI) was 
carried out by adding 5 mg of PEI to 10 mg of UR-NPs 
dispersed in 2 mL of PBS. The coating was carried out at 37 
o
C 
for 3 h. The product was washed several times with PBS, 
centrifuged and dried under a vacuum at 25 
o
C.  
Cargo loading and release. Cargo loading: 20 mg of UR-NPs 
were placed in a glass vial with a septum and dried at 80 
o
C 
under vacuum for 24 h. Then, the vial was placed at 4 
o
C with 
magnetic stirring and 5 mL of cargo solution (20 mg mL
-1 
fluorescein in PBS) were added and the suspension was stirred 
for 24 h. After that time, the sample was filtered and washed 
twice with warm PBS (50 
o
C) to remove the potential 
fluorescein absorbed on the external surface. Note that the 
cargo loading was performed at 4 
o
C, below than the lower 
critical solution temperature (LCST) which means that the 
polymer presents an extended conformation (pores opened). 
After loading, the temperature was increased to 50 
o
C (above 
the LCST) which induces the polymer to collapse, closing the 
pore entrances.
15
 After that, loaded UR-NPs were coated with 
PEI in a similar way to that above described.  
In vial cargo Release: 9 mg of fluorescein-loaded 
nanoparticles were suspended in 1.8 mL of PBS pH 7.4 (10 
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mM). Then, 0.5 mL of that UR-NPs suspension were placed on 
a Transwell® permeable support with 0.4 µm of polycarbonate 
membrane (3 replicas were performed). The well was filled 
with 1.5 mL of PBS and the suspension was stirred at 37 
o
C and 
100 rpm during all the experiment. For the US experiments 
the particles suspension was subjected to US exposure (10 min 
at 1.3 MHz and 100 W) before placing it on the Transwell® 
insert. The amount of fluorescein released after 16 h was 
determined by fluorescence spectrometry (λexc 490, λem 514 
nm). 
In vivo evaluation of US Responsive Nanoparticles 
The in vivo US-responsiveness of UR-NPs@PEI was evaluated 
on a mouse model (FVB strain).  Mice were shaved and 
depilatory cream was employed to remove their hair in the 
area that was evaluated (to prevent auto-fluorescence and to 
apply the ultrasound gel). Nanoparticles were covalently 
labeled with Rhodamine B, as previously mentioned, to be 
able to visualize the NPs by in vivo fluorescence imaging (In 
vivo Xtreme®, Bruker). Loading of Calcein-AM was performed 
following the same procedure as previously described but 
using a 2 mg mL
-1
 solution of the cargo in a mixture of DMSO 
and PBS (the material was washed several times with PBS 
after cargo loading). Calcein-AM loaded nanoparticles were 
injected subcutaneously and bilaterally in mice (2 mg of NPs in 
100 μL PBS per injection). US was applied at the left injection 
site (1 MHz, 3 W cm
-2
, 10 min continuous application) and 
using ultrasound gel. In vivo fluorescence was evaluated at 
different wavelengths (Green: λexc 490, λem 514 nm, Red: λexc 
540, λem 625 nm), before and after US application. 
 
Ultrasound-Responsive Nanoparticles-Cell Platform 
Human placentas from healthy mothers were obtained from 
the Department of Obstetrics and Gynecology under written 
informed consent approved by the Ethics Committee from 
Hospital Universitario 12 de Octubre, Madrid, Spain. 
Processing of placental membranes and culture of primary 
cells (DMSCs) were done as previously reported.
33,34
  
Cellular uptake of Nanoparticles. DMSCs were plated 24 h 
before starting the experiment in culture multiwell plates at a 
density of 10
4
 cells per cm
2
. After incubation with particles 
(UR-NPs and UR-NPs@PEI) in serum-free culture medium (200 
µg mL
-1
) for 2 h, the media were removed and the cells were 
washed with PBS three times. Then, the cells were fixed with 
Z-fix solution (Anatech, USA) for 15 min, permeabilized with 
0.1 % Triton X-100 in PBS at room temperature for 5 min and, 
subsequently incubated for 20 min with Alexa Fluor®568 
phalloidin (Invitrogen, Spain) for staining F-actin. DAPI (4’,6-
diamidino-2-phenylindole) at 1 μg mL
-1 
was used to stain and 
visualize the nuclei. Fluorescence microscopy was performed 
with an Evos® FL Cell Imaging System equipped with tree Led 
Lights Cubes (λexc (nm); λem (nm)): DAPI (357/44; 447/60), GFP 
(470/22; 525/50), RFP (531/40; 593/40) from AMG (Advance 
Microscopy Group). Quantitative analysis of cellular uptake 
was performed by flow cytometry (FACS). 200 µg mL
-1
 
particles were incubated with the DMSCs for 2 h, and then 
removed by washing three times with PBS. Subsequently, the 
cells were trypsinized, collected by centrifugation and 
redispersed in PBS solution with trypan blue (0.5 %) to remove 
extracellular fluorescence. The fluorescence intensity of 
10,000 cells was quantified by FACS. Statistical analysis for 
differences between groups was carried out by the Student´s t 
test. 
Quantitative analysis of particle retention was performed 
by FACS. Particles at a concentration of 200 µg mL
-1 
were 
incubated with the DMSCs for 2 h, and then removed by 
washing three times with PBS. The cells were then cultured in 
fresh medium for indicated time points. Subsequently, the 
cells were collected by trypsinization and centrifugation, and 
redispersed in PBS solution with trypan blue (0.5 %). The 
fluorescence intensity of 10,000 cells was quantified by FACS. 
The fluorescence intensities obtained after the first day were 
corrected by the cell dilution folds due to cell division. 
Cytotoxicity of Nanoparticles. The cytotoxicity of both, UR-
NPs and UR-NPs@PEI, was evaluated using the following 
standard protocols:  
Lactate dehydrogenase (LDH) activity test: Extracellular LDH 
activity was measured in the media using the kit for 
Quantitative determination of LDH (Spinreact, Spain). DMSCs 
were incubated with different sets of NPs for 2 h at different 
concentrations in serum-free DMEM (n=3). Then, the media 
were changed with fresh complete culture media and the cells 
were incubated for another 24 h. The culture medium was 
then collected to determine the extracellular LDH activity, 
measured by means of a spectrophotometer (at 340 nm) 
following the manufacturer´s protocol. 
MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
assay: The MTS reduction assay was performed using a 
commercial assay and following the manufacturer´s protocol 
(CellTiter® Aqueous One Solution Cell Proliferation Assay). 
Briefly, DMSCs were incubated with various concentrations of 
NPs for 2 h in serum-free DMEM (n=3). Then, the media were 
changed with fresh complete culture media and the cells were 
incubated for another 24 h. The medium was replaced with 
600 µL culture medium including MTS, and the incubation 
proceeded for 3 h. The medium was then removed, and its 
absorption at 490 nm was measured using a 
spectrofluorimeter plate reader (EnSpire, PerkinElmer). 
Intracellular fate of Nanoparticles. For the co-localization of 
NPs and lysosomes, the cells were incubated with 200 µg mL
-1 
particles for 2 h. The cells were washed twice with PBS 
solution. Then, lysosomes were stained with the Cell Tracker
®
 
Lysosome staining kit following the manufacturer´s protocol 
(AAT Bioquest, Inc, USA). After washing twice with PBS, fresh 
medium was added. The cells were fixed and stained with 
DAPI as previously described. Fluorescence microscopy was 
performed with an Evos® FL Cell Imaging System. 
In vitro evaluation of Ultrasonic Responsive cell platform. 
Preparation of UR-NPs@PEI containing Doxorubicin was 
performed by stirring 10 mg of UR-NPs in 5 mL of a solution of 
doxorubicin in PBS (1 mg mL
-1
) for 24 h at 4 
o
C. Doxorubicin-
loaded particles were washed by centrifugation and 
redispersion in PBS at 50 
o
C several times. Loaded 
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nanoparticles were coated with PEI as previously described 
(DOX-UR-NPs@PEI). Quantification of doxorubicin inside DOX-
UR-NPs@PEI was performed by dispersing a known amount of 
nanoparticles in 95% ethanol in an ultrasonic bath to force the 
release of the cargo, and measuring the fluorescence of 
doxorubicin in ethanolic solution after filtration of the 
nanoparticles. A calibration curve of doxorubicin fluorescence 
in ethanolic solution (λexc 470, λem 585 nm) was used. 
The preparation of the engineered cell-NPs platform was 
carried out by the following procedure: DMSCs were 
incubated with 200 µg mL
-1 
of UR-NP@PEI (with/without DOX) 
for 2 h and washed with PBS to remove non-internalized 
nanoparticles. Quantification of doxorubicin in the DOX-
Platform was carried out as described for DOX-UR-NPs@PEI, 
dispersing the DOX-Platform in 95% ethanol under sonication 
(therefore, releasing the cell content, including the 
nanoparticles, to the ethanolic solution) and measuring the 
fluorescence. 
Cell viability was evaluated after 1 and 3 days by Alamar 
Blue assay, following the manufacturer´s instructions: 10 % of 
the reagent was added to the culture medium with the DMSCs 
and incubated at 37 
o
C for 1 h. Then, fluorescence at λexc 560, 
λem 590 nm was measured in a spectrofluorimeter plate 
reader. Cell viability was then analyzed as a percentage of the 
control wells (DMSCs not exposed to DOX-Nanoparticles). 
Migration capacity towards mammary tumor homogenate. 
Animal Care was carried out in accordance with the Royal 
Decree 223/1988 (BOE 8, 18) and the Ministerial Order of 13 
October 1989 (BOE 8) regarding the protection of 
experimental animals, as well as with the European Council 
Directive 86/609/EEC and approved by the Committee of 
Ethics and Animal Welfare (CEBA) from Hospital Universitario 
12 de Octubre. N-nitroso-N-methylurea (NMU) tumors were 
induced in 45-day-old Sprague-Dawley female rats according 
to our previously published protocol
46
. The tumors were 
disected out from the animals, immediately frozen in liquid 
nitrogen and subsequently stored at -80 
o
C until further use. 
Homogenates from those tumors were performed at 4 
o
C as 
we previously described.
34
 The protein concentration was 
measured using the Lowry protein assay kit (Biorad, Spain) 
following the manufacturer´s instructions. 
The migration capacity of the engineered platform towards 
tumor homogenate was performed using Millicell culture plate 
inserts with 8 μm pore polycarbonate membranes (Merk 
Millipore, Spain) in 24-well plates. 1.5x10
5
 DMSCs containing 
UR-NPs@PEI (with/without DOX) in 300 µL of serum-free 
DMEM were seeded in the insert. Tumor homogenate (5 mg 
mL
-1 
of protein concentration) was added in the well below. 
Migration medium (serum-free DMEM) without tissue was 
used as a negative control. Migration was assessed at 24 h by 
the CytoSelect 24-Well Cell Migration Assay (8 μm, 
Colorimetric, Cell Biolabs, Bionova Cientifica, S.L., Spain). Non-
migratory cells were removed from the top of the membrane 
and migratory cells on the bottom of the polycarbonate 
membrane were stained with the Cell Stain Solution and 
quantified according to manufacturer´s instructions. Migratory 
cells were visualized (three individual fields per insert) using a 
light microscope under x40 magnification objective. Color of 
stained cells was subsequently extracted with the Extraction 
Solution, and quantified by absorbance at 560 nm using the 
multimodal plate reader Enspire (Perkin Elmer). All 
experiments were done as a minimum in triplicate. 
In vitro co-culture experiments. DMSCs or the engineered 
DOX-Platform (UR-NPs@PEI inside DMSCs, with doxorubicin) 
were co-cultured with NMU rat mammary cancer cells (ATCC, 
LGC Standards S.L.U., Spain). NMU cells were cultured in 24 
well plates at a density of 20,000 cells per well 24 h before the 
experiment was carried out. DMSCs were incubated with DOX-
UR-NPs@PEI as previously described. After washing non 
internalized nanoparticles, DMSCs (with and without NPs) 
were trypsinized and ultrasound was applied to some of the 
DMSCs suspensions (1 MHz, 3 Wcm
-2
, 5 min continuous 
application). Then, DMSCs with or without DOX-NPs (and with 
or without US exposure) were seeded in Transwell
®
 culture 
inserts (0.4 µm pore, polycarbonate membranes, tissue 
cultured treated, Costar®), in the same plate containing NMU 
cells, in two different DMSCs:NMU ratios (1:2 and 1:5). After 1 
and 2 days, the inserts were removed and NMU cells viability 
was analyzed by Alamar Blue test, as previously described. 
 
Ultrasonic experiments.  
For the in vial release experiments, the US experiments were 
performed in a commercial laboratory ultrasound apparatus 
(RBI, France), working at 1.3 MHz and 100 W during 10 min, in 
similar conditions to those described in our previous work.
15
  
For the in vivo and in vitro intracellular cargo release 
experiments, a commercial ultrasound apparatus for 
application in physical therapy was used (New Pocket Sonovit, 
New Age Italia Srl, Italy). The parameters selected were: 1 
MHz, 3 W cm
-2
, continuous application, 5-10 min. In the in 
vitro intracellular experiments, ultrasound was applied from 
the top of a filled culture well through a latex membrane 
(ultrasound transmission gel was placed between the 
transducer and the latex membrane). 
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